Stockscreener 앱 받기
1.31
12.42%
-0.22
Estrella Immunopharma Inc 주식(ESLA)의 최신 뉴스
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference - Business Wire
Is Estrella (ESLAW) stock a safe investment |Cash Flow - Newser
Eureka-led Estrella (NASDAQ: ESLA) details 59.3% control and board pay - Stock Titan
Estrella Immunopharma CFO Xu Jiandong buys $2,594 in stock - Investing.com
Estrella Immunopharma CFO Xu Jiandong buys $2,594 in stock By Investing.com - Investing.com Canada
Estrella Immunopharma (ESLA) CFO boosts stake with small share buys - Stock Titan
ESLA Estrella Immunopharma falls 3.92% after Q1 2026 EPS misses analyst forecasts by a wide 90.6% margin.Growth Phase - Newser
Is Estrella (ESLAW) stock a good option for investors |High Volatility - Newser
Estrella Immunopharma (ESLA) Stock: Changing Trend? (Institutional Selling) 2026-04-27Breakout Confirmation - Newser
Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Declines By 57.6% - MarketBeat
OneIM Acquisition Corp. (OIM) - Minichart
Estrella Immunopharma (ESLA) Management Strategy | Q1 2026: Below ExpectationsStrong Sell - Cổng thông tin điện tử tỉnh Tây Ninh
Robinson Opportunistic Income Fund's Estrella Immunopharma Inc(ESLAW) Holding History - GuruFocus
Estrella Immunopharma (ESLA) Stock Dividend Yield (Drifts Lower) 2026-04-20Most Discussed Stocks - Cổng thông tin điện tử tỉnh Lào Cai
ESLA (Estrella Immunopharma Inc.) reports wider than expected Q1 2026 EPS loss but shares rise 13 percent in regular trading.CFO Commentary - Newser
Estrella Immunopharma, Inc. (ESLAW) - Minichart
Estrella Immunopharma (ESLA) Stock: Increase Exposure? (Dips) 2026-04-16Trending Volume Leaders - Cổng thông tin điện tử Tỉnh Sơn La
Sectors Review: Should you buy the dip on Estrella Immunopharma Inc2026 Retail Activity & Daily Profit Maximizing Tips - baoquankhu1.vn
Published on: 2026-04-09 23:33:21 - baoquankhu1.vn
Quarterly Recap: Is Estrella Immunopharma Inc stock a good pick for beginnersQuarterly Investment Review & Safe Capital Growth Stock Tips - baoquankhu1.vn
Is Estrella Immunopharma (ESLA) Stock a Buy Now | Price at $1.88, Up 9.30%Crowd Entry Points - Newser
12 Health Care Stocks Moving In Tuesday's Intraday Session - Sahm
Aug Drivers: Will Estrella Immunopharma Inc benefit from current market trendsPortfolio Performance Report & Verified Technical Signals - baoquankhu1.vn
Is Estrella (ESLAW) Stock Trending Down | Price at $0.09, Up 20.29%Shared Momentum Picks - Newser
ESLA Should I Buy - Intellectia AI
Aug Outlook: Should you buy the dip on Estrella Immunopharma Inc2026 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Estrella Immunopharma ESLA US - Smartkarma
Insider Sell: Is Estrella Immunopharma Inc stock technically oversold2026 Fed Impact & Verified Short-Term Plans - baoquankhu1.vn
Silexion Granted Approval to Launch Human Trials That Could Redefine the Future of Cancer Treatment - Benzinga
Top Curanex Pharmaceuticals (CURX) Competitors 2026 - MarketBeat
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research - BioSpace
Masco Corporation Announces Date for Earnings Release and Conference Call for 2026 First Quarter - weeklyvoice.com
If You Invested $1,000 in Estrella Immunopharma (ESLA) - Stock Titan
Estrella Immunopharma, Inc.: Fundamental Analysis and Financial Ratings | ESLA | US2975841048 - MarketScreener
Estrella Immunopharma: Advancing Next-Generation T-Cell Therapies for Cancer and Autoimmune Diseases - Minichart
Estrella 10-K: Net loss widens to $13.1M in 2025; cash $1.4M, working capital deficit $11.9M - TradingView
ESLA PE Ratio & Valuation, Is ESLA Overvalued - Intellectia AI
EB103 lymphoma trial data and pipeline update from Estrella (NASDAQ: ESLA) - Stock Titan
Certain Common Stock of Estrella Immunopharma, Inc. are subject to a Lock-Up Agreement Ending on 8-MAR-2026. - marketscreener.com
Gainers Report: Is Estrella Immunopharma Inc stock a good pick for beginnersJuly 2025 Chart Watch & Intraday High Probability Setup Alerts - baoquankhu1.vn
ESLA Earnings History & Surprises | EPS & Revenue Results | ESTRELLA IMMUNOPHARMA INC (NASDAQ:ESLA) - ChartMill
Volume Summary: Is Estrella Immunopharma Inc currently under institutional pressureJuly 2025 Momentum & Low Volatility Stock Suggestions - baoquankhu1.vn
ESLAW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ESLA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ESLA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
What’s next for Estrella Immunopharma Inc. stockJuly 2025 Decliners & Accurate Entry and Exit Point Alerts - mfd.ru
Travel Stocks: Is Estrella Immunopharma Inc part of any ETFWeekly Investment Recap & Weekly Momentum Picks - baoquankhu1.vn
Will Estrella Immunopharma Inc. benefit from government policyJuly 2025 Trade Ideas & Step-by-Step Swing Trade Plans - mfd.ru
Can Estrella Immunopharma Inc. sustain its profitabilityMarket Trend Summary & Short-Term Trading Opportunity Alerts - mfd.ru
Why Estrella Immunopharma Inc. stock is recommended by analystsMarket Movement Recap & Consistent Income Trade Ideas - mfd.ru
ESLA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Portfolio Update: Will Estrella Immunopharma Inc benefit from government policy2025 Growth vs Value & Accurate Intraday Trade Tips - baoquankhu1.vn
Estrella reports 100% complete response rate in lymphoma trial By Investing.com - Investing.com South Africa
Estrella reports 100% complete response rate in lymphoma trial - Investing.com Nigeria
Merger Talk: Is INFA a strong growth stock2025 Dividend Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL - Yahoo Finance
D. Boral Capital Reiterates Buy Rating for Estrella Immunopharma (NASDAQ:ESLA) - MarketBeat
0.78%
3.99%
자본화:
|
볼륨(24시간):